TRADING UPDATES: Nostra revenue rises; Synergia eyes Cambay farm-out
(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News:
Read moreFri, 02nd Oct 2020 10:10
(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read more(Sharecast News) - Women's health-focussed biopharmaceutical company Ovoca Bio announced the successful completion of participant enrollment in a phase 2 dose-ranging study assessing 'orenetide' on Friday.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read moreEXECUTIVE CHANGES: MP Evans promotes Finance Director Coulson as CEO
Read moreTRADING UPDATES: Strong annual results from Springfield, Fiske
Read moreUK shareholder meetings calendar - next 7 days
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreTRADING UPDATES: Character Extends Peppa Pig Deal; Dekel Raises Cash
Read more(Sharecast News) - Biopharmaceutical company Ovoca Bio said on Friday that the first patient has been enrolled in a phase 2 dose-ranging study assessing 'BP-101', which it described as a novel treatment for premenopausal women with hypoactive sexual desire disorder (HSDD) - a condition characterised by a distressing lack or loss of sexual desire.
Read moreIN BRIEF: Ovoca Refiles Marketing Application With Russian Regulator
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreIN BRIEF: Ovoca Bio Names Wiltshire As Chief Business Officer
Read more(Sharecast News) - Women's health-focussed biopharmaceuticals company Ovoca Bio announced the appointment of Christopher Wiltshire as its chief business officer and executive director of the board on Friday, effective immediately.
Read more